159837 生物科技
已收盘 01-12 15:00:00
资讯
新帖
简况
生物科技公司Alveus融资1.6亿美元，专攻减重维持难题
环球市场播报 · 01-08
生物科技公司Alveus融资1.6亿美元，专攻减重维持难题
抗癌生物科技公司Aktis Oncology(AKTS.US)IPO定价16-18美元/股 拟筹资2.12亿美元
智通财经 · 01-05
抗癌生物科技公司Aktis Oncology(AKTS.US)IPO定价16-18美元/股 拟筹资2.12亿美元
肿瘤生物科技公司 时迈药业-B，赴港IPO 四项事项待补充说明
中金财经 · 2025-12-30
肿瘤生物科技公司 时迈药业-B，赴港IPO 四项事项待补充说明
冰与火之歌：宝济药业(02589)180%暴涨vs华芢生物(02396)、翰思艾泰(03378)腰斩 港股生物科技新股极端分化启示录
智通财经网 · 2025-12-24
冰与火之歌：宝济药业(02589)180%暴涨vs华芢生物(02396)、翰思艾泰(03378)腰斩 港股生物科技新股极端分化启示录
华资实业(600191.SH)拟设立包头恒鲁生物科技有限公司
智通财经 · 2025-12-18
华资实业(600191.SH)拟设立包头恒鲁生物科技有限公司
AI生物科技公司英硅智能香港IPO拟筹资约22.8亿港元
格隆汇 · 2025-12-18
AI生物科技公司英硅智能香港IPO拟筹资约22.8亿港元
招商中证生物科技主题ETF基金经理变动：增聘窦福成为基金经理
证券之星 · 2025-12-16
招商中证生物科技主题ETF基金经理变动：增聘窦福成为基金经理
生物科技企业上海君赛生物 递表港交所
中金财经 · 2025-12-10
生物科技企业上海君赛生物 递表港交所
华芢生物科技（青岛）股份有限公司- B已递交聆讯后资料集
中金财经 · 2025-12-10
华芢生物科技（青岛）股份有限公司- B已递交聆讯后资料集
天润乳业：控股子公司新疆天润生物科技获政府补助6850440.00元
证券日报网 · 2025-12-07
天润乳业：控股子公司新疆天润生物科技获政府补助6850440.00元
怡达股份(300721.SZ)子公司拟收购万淇生物科技(泰州)85%股权
智通财经 · 2025-11-28
怡达股份(300721.SZ)子公司拟收购万淇生物科技(泰州)85%股权
11月27日华资实业（600191）涨停分析：生物科技转型、黄原胶投产驱动
证券之星 · 2025-11-27
11月27日华资实业（600191）涨停分析：生物科技转型、黄原胶投产驱动
司美格鲁肽阿尔茨海默病临床失败；两家生物科技公司递表港股IPO | 医药早参
每日经济新闻 · 2025-11-26
司美格鲁肽阿尔茨海默病临床失败；两家生物科技公司递表港股IPO | 医药早参
11月20日华资实业（600191）涨停分析：生物科技转型、黄原胶投产驱动
证券之星 · 2025-11-20
11月20日华资实业（600191）涨停分析：生物科技转型、黄原胶投产驱动
迦南科技：生物发酵系统等设备可支持合成生物科技
证券之星 · 2025-11-13
迦南科技：生物发酵系统等设备可支持合成生物科技
新和成：公司与中石化合资设立宁波镇海炼化新和成生物科技有限公司
证券日报 · 2025-11-06
新和成：公司与中石化合资设立宁波镇海炼化新和成生物科技有限公司
普洛药业最新公告：与嘉兴安帝康生物科技签署战略合作框架协议
证券之星 · 2025-11-06
普洛药业最新公告：与嘉兴安帝康生物科技签署战略合作框架协议
港股前十月IPO募资额全球居首 生物科技板块表现亮眼
财闻 · 2025-11-04
港股前十月IPO募资额全球居首 生物科技板块表现亮眼
生物科技企业密集上市 中国创新药加速全球化布局
证券日报网 · 2025-11-02
生物科技企业密集上市 中国创新药加速全球化布局
医药创新投资大会在南宁举办 港交所：香港重新成为生物科技企业首选上市目的地
智通财经 · 2025-10-30
医药创新投资大会在南宁举办 港交所：香港重新成为生物科技企业首选上市目的地
加载更多
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159837","market":"SZ","secType":"STK","nameCN":"生物科技","latestPrice":0.539,"timestamp":1768201431000,"preClose":0.536,"halted":0,"volume":66312339,"delay":0,"changeRate":0.0056,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":0.003,"latestTime":"01-12 15:00:00","open":0.537,"high":0.542,"low":0.533,"amount":35651100,"amplitude":0.0168,"askPrice":0.54,"askSize":13977,"bidPrice":0.539,"bidSize":2688,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768267800000},"marketStatusCode":5,"adr":0,"adjPreClose":0.536,"symbolType":"fund","openAndCloseTimeList":[[1768181400000,1768188600000],[1768194000000,1768201200000]],"highLimit":0.59,"lowLimit":0.482,"ibTradeSell":false,"ibTradeBuySell":true,"isCdr":false,"pbRate":0,"committee":-0.105862,"marketValue":0,"turnoverRate":0,"status":0,"floatMarketCap":0},"requestUrl":"/m/hq/s/159837","defaultTab":"news","newsList":[{"id":"2601360679","title":"生物科技公司Alveus融资1.6亿美元，专攻减重维持难题","url":"https://stock-news.laohu8.com/highlight/detail?id=2601360679","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601360679?lang=zh_cn&edition=full","pubTime":"2026-01-08 22:12","pubTimestamp":1767881520,"startTime":"0","endTime":"0","summary":"生物科技企业Alveus治疗公司于周四宣布，已完成 1.598 亿美元融资，这笔资金将用于研发肥胖症治疗方案，重点解决患者长期维持减重效果的难题。该公司表示，这正是现有疗法未能攻克的痛点。Alveus首席执行官拉吉坎南表示，公司的研发目标聚焦于减重效果维持、提升用药耐受性以及优化身体成分，而非简单地追求减重磅数最大化。 美国国立卫生研究院的数据显示，截至 2024 年，美国成年人的肥胖率已超过 40%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-01-08/doc-inhfreqi3649127.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159837"],"gpt_icon":0},{"id":"2601988176","title":"抗癌生物科技公司Aktis Oncology(AKTS.US)IPO定价16-18美元/股 拟筹资2.12亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601988176","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601988176?lang=zh_cn&edition=full","pubTime":"2026-01-05 21:16","pubTimestamp":1767619009,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，专注于放射性药物疗法研发的临床阶段生物科技公司Aktis Oncology Inc.计划在美国进行首次公开募股，筹资至多2.12亿美元。此次拟议上市正值2026年初可能迎来一波密集IPO之际。目前，Aktis已从包括MPM、Vida、EcoR1 Capital和Blue Owl Capital在内的顶尖生命科学机构投资者财团筹集了约3.46亿美元。招股文件还披露，IPO前，MPM关联公司持有Aktis 26%的股份，Vida Ventures持有14%，EcoR1持有11%，Blue Owl持有7%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388886.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AKTS","159837","BK4148"],"gpt_icon":0},{"id":"2595765343","title":"肿瘤生物科技公司 时迈药业-B，赴港IPO 四项事项待补充说明","url":"https://stock-news.laohu8.com/highlight/detail?id=2595765343","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595765343?lang=zh_cn&edition=full","pubTime":"2025-12-30 12:10","pubTimestamp":1767067802,"startTime":"0","endTime":"0","summary":"三、请发行人结合药物研发技术路线等情况说明发行人及下属公司经营范围、实际业务是否涉及“人体干细胞、基因诊断与治疗技术开发和应用”或其他外商投资准入限制或禁止领域及相关判断依据，本次发行上市及“全流通”前后是否持续符合外商投资准入政策要求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251230/31902864.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["159837"],"gpt_icon":0},{"id":"2593942679","title":"冰与火之歌：宝济药业(02589)180%暴涨vs华芢生物(02396)、翰思艾泰(03378)腰斩 港股生物科技新股极端分化启示录","url":"https://stock-news.laohu8.com/highlight/detail?id=2593942679","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593942679?lang=zh_cn&edition=full","pubTime":"2025-12-24 12:47","pubTimestamp":1766551655,"startTime":"0","endTime":"0","summary":"2025年12月，港股IPO市场上演了一场令人瞠目结舌的“冰与火之歌”。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20251224/20251224125033_33927.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251224/20251224125033_33927.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385346.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1535","BK1616","BK1173","03378","02659","02589","02396","159837","BK1233","BK1587"],"gpt_icon":1},{"id":"2592971519","title":"华资实业(600191.SH)拟设立包头恒鲁生物科技有限公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2592971519","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592971519?lang=zh_cn&edition=full","pubTime":"2025-12-18 17:37","pubTimestamp":1766050650,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华资实业 发布公告，公司拟成立全资子公司“包头恒鲁生物科技有限公司”，注册资本1000万元，由公司100%出资。本次子公司设立，是为了切实推进公司“创新驱动、多元布局，推动产业升级”发展战略。公司现有产品包括黄原胶、抗性糊精等产品。前述新产品的开发，将有助于公司持续拉长产业链，提升产品价值链。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383166.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600191","BK0199","159837","BK0238","BK0074"],"gpt_icon":0},{"id":"2592694178","title":"AI生物科技公司英硅智能香港IPO拟筹资约22.8亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2592694178","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592694178?lang=zh_cn&edition=full","pubTime":"2025-12-18 07:49","pubTimestamp":1766015377,"startTime":"0","endTime":"0","summary":"12月18日，根据呈交香港交易所的公告，英硅智能在香港发售约9500万股股份，每股价格为24.05港元。计算显示，该公司计划筹资约22.8亿港元（2.93亿美元）。公司预计将于12月30日挂牌上市，摩根士丹利、中金和广发证券是联席保荐人。公司网站显示，英硅智能是一家由人工智能(AI)驱动的生物技术公司，旨在利用其专有的Pharma.AI平台加速药物发现。\n\n港股频道更多独家策划、专家专栏，免费查阅>>\n\r\n 责任编辑：栎树","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2025/12/18074954723249.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["159837"],"gpt_icon":0},{"id":"2591054676","title":"招商中证生物科技主题ETF基金经理变动：增聘窦福成为基金经理","url":"https://stock-news.laohu8.com/highlight/detail?id=2591054676","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591054676?lang=zh_cn&edition=full","pubTime":"2025-12-16 09:31","pubTimestamp":1765848698,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年12月16日，招商中证生物科技主题ETF发布公告，增聘窦福成为基金经理，任职日期自2025年12月16日起，房俊一不再担任该基金基金经理，离任日期为2025年12月16日，变更后招商中证生物科技主题ETF的基金经理为窦福成。截止2025年12月15日，招商中证生物科技主题ETF净值为0.5157，较上一日下跌2.07%，近一年上涨6.66%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600007415.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159837"],"gpt_icon":0},{"id":"2590588959","title":"生物科技企业上海君赛生物 递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2590588959","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590588959?lang=zh_cn&edition=full","pubTime":"2025-12-10 17:20","pubTimestamp":1765358401,"startTime":"0","endTime":"0","summary":"览富财经网讯：12月10日，上海君赛生物股份有限公司 - B(简称：君赛生物)向港交所递表，拟在香港主板上市。 据招股书披露，君赛生物是一家致力于实体瘤创新细胞疗法与创新药开发的生物科技企业，专注开发更安全、更有效、更可及、更可负担的免疫细胞疗法，不受任何固定分子靶点限制，覆盖最常见或最难治的实体肿瘤。根据弗若斯特沙利文的资料，公司的核心产品GC101是全球首款无需高强度清淋化疗、无需IL-2给药的肿瘤浸润淋巴细胞(TIL)疗 法，有望成为中国首个获批上市的TIL疗法。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202512/10/20251210616705.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202512/10/20251210616705.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251210/31856583.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["HEXmain","159837"],"gpt_icon":0},{"id":"2590742372","title":"华芢生物科技（青岛）股份有限公司- B已递交聆讯后资料集","url":"https://stock-news.laohu8.com/highlight/detail?id=2590742372","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590742372?lang=zh_cn&edition=full","pubTime":"2025-12-10 11:40","pubTimestamp":1765338001,"startTime":"0","endTime":"0","summary":"览富财经网讯：12月10日，港交所官网显示，华芢生物科技(青岛)股份有限公司 - B(简称：华芢生物)已递交聆讯后资料集，登陆香港联合交易所主板指日可待。 据了解，华芢生物成立于2012年，是一家总部位于中国的生物制药公司，致力于开发疗法，重点是针对有医疗需求及市场机会的适应症开发蛋白质药物。公司的主攻方向是发现、开 发和商业化伤口愈合的疗法，目前为PDGF药物。截至最后实际可行日期，我华芢生物的管线包含十款候选产品，其中七款为PDGF候选药物，包括两款核心产品，即用于治疗烧烫 伤的Pro-101-1及用于治疗糖足的Pro-101-2，是rhPDGF-BB药物。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202512/10/20251210969933.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202512/10/20251210969933.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251210/31855721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["159837","02396"],"gpt_icon":0},{"id":"2589500870","title":"天润乳业：控股子公司新疆天润生物科技获政府补助6850440.00元","url":"https://stock-news.laohu8.com/highlight/detail?id=2589500870","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589500870?lang=zh_cn&edition=full","pubTime":"2025-12-07 20:38","pubTimestamp":1765111080,"startTime":"0","endTime":"0","summary":"证券日报网讯12月5日晚间，天润乳业发布公告称，控股子公司新疆天润生物科技股份有限公司收到政府补助6，850，440.00元，为与收益相关的政府补助，占公司2024年度经审计归属于上市公司股东的净利润的15.69%，预计将增加公司2025年度归属于上市公司股东的净利润6，850，440.00元。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-07/doc-infzyxcx4635092.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-07/doc-infzyxcx4635092.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0226","600419","BK0048","159837"],"gpt_icon":0},{"id":"2586783782","title":"怡达股份(300721.SZ)子公司拟收购万淇生物科技(泰州)85%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2586783782","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586783782?lang=zh_cn&edition=full","pubTime":"2025-11-28 18:09","pubTimestamp":1764324549,"startTime":"0","endTime":"0","summary":"智通财经APP讯，怡达股份(300721.SZ)公告，公司控股子公司泰兴怡达化学有限公司(简称“泰兴怡达”)以自有资金2456.5万元收购江苏万淇生物科技股份有限公司(简称“万淇股份”)持有的万淇生物科技(泰州)有限公司85%股权。该事项旨在落实公司高质量发展战略，推进产品高端化、精细化发展，利用万淇股份多年的生产经验和销售渠道优势，与其合作推进环氧丙(乙)烷衍生品在精细化工领域的建设投入，进一步优化公司产能布局、丰富公司产品线，提升公司生产能力以有效满足下游客户需求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375197.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300721","159837","BK0229"],"gpt_icon":0},{"id":"2586212160","title":"11月27日华资实业（600191）涨停分析：生物科技转型、黄原胶投产驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2586212160","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586212160?lang=zh_cn&edition=full","pubTime":"2025-11-27 15:16","pubTimestamp":1764227780,"startTime":"0","endTime":"0","summary":"证券之星消息，华资实业11月27日涨停收盘，收盘价11.32元。该股于13点3分涨停，未打开涨停，截止收盘封单资金为2170.95万元，占其流通市值0.4%。近5日资金流向一览见下表：该股为内蒙古概念，调味品，食品概念热股，当日内蒙古概念概念上涨0.93%，调味品概念上涨0.15%，食品概念上涨0.05%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112700016857.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159837","BK0238","BK0074","BK0199","600191"],"gpt_icon":0},{"id":"2586340204","title":"司美格鲁肽阿尔茨海默病临床失败；两家生物科技公司递表港股IPO | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2586340204","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586340204?lang=zh_cn&edition=full","pubTime":"2025-11-26 07:08","pubTimestamp":1764112118,"startTime":"0","endTime":"0","summary":"丨2025年11月26日星期三丨NO.1司美格鲁肽治疗阿尔茨海默病的临床试验失败11月24日，诺和诺德宣布，其针对司美格鲁肽治疗阿尔茨海默病的两项大型Ⅲ期试验均未达到主要目标。数据显示，与安慰剂相比，用药患者病情进展未获显著延缓。受此消息影响，公司股价大跌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511263574622438.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511263574622438.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159837","09939","159938","BK1574","BK1161","BK1515"],"gpt_icon":0},{"id":"2584818316","title":"11月20日华资实业（600191）涨停分析：生物科技转型、黄原胶投产驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2584818316","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584818316?lang=zh_cn&edition=full","pubTime":"2025-11-20 15:16","pubTimestamp":1763622982,"startTime":"0","endTime":"0","summary":"证券之星消息，华资实业11月20日涨停收盘，收盘价10.45元。该股于9点44分涨停，未打开涨停，截止收盘封单资金为5079.95万元，占其流通市值1.0%。近5日资金流向一览见下表：该股为内蒙古概念，调味品，白糖概念热股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000017340.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600191","159837","BK0238","BK0199","BK0074"],"gpt_icon":0},{"id":"2583551265","title":"迦南科技：生物发酵系统等设备可支持合成生物科技","url":"https://stock-news.laohu8.com/highlight/detail?id=2583551265","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583551265?lang=zh_cn&edition=full","pubTime":"2025-11-13 16:00","pubTimestamp":1763020848,"startTime":"0","endTime":"0","summary":"证券之星消息，迦南科技(300412)11月13日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘好，请问十五五规划中合成生物为第二个重点攻关发展专题，请问贵公司哪些设备可以支持合生生物科技？？迦南科技回复：您好，合成生物学是一个非常广阔的领域，在制药行业中有广泛的应用，公司主要业务为制药装备，持续围绕生命大健康产业做战略布局。例如公司的生物发酵系统、配液系统、冻干系统、制剂设备系列等，均可根据客户需求提供。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300024933.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","159837","BK0028","300412","BK0132"],"gpt_icon":0},{"id":"2581096989","title":"新和成：公司与中石化合资设立宁波镇海炼化新和成生物科技有限公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2581096989","media":"证券日报 ","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581096989?lang=zh_cn&edition=full","pubTime":"2025-11-06 21:04","pubTimestamp":1762434240,"startTime":"0","endTime":"0","summary":"证券日报网讯新和成11月6日发布公告，在公司回答调研者提问时表示，公司与中石化合资设立宁波镇海炼化新和成生物科技有限公司，合作投建18万吨/年（折纯）液体蛋氨酸项目，项目结合前期试生产情况于2025年9月份安排了检修，正在检修后开展复产工作。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-06/doc-infwnsqp3217177.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-06/doc-infwnsqp3217177.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159837","BK0188","002001","BK0028","BK0191","BK0070","BK0197","BK0187","LU0405327148.USD","LU0405327494.USD","BK0239"],"gpt_icon":0},{"id":"2581508065","title":"普洛药业最新公告：与嘉兴安帝康生物科技签署战略合作框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2581508065","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581508065?lang=zh_cn&edition=full","pubTime":"2025-11-06 18:51","pubTimestamp":1762426288,"startTime":"0","endTime":"0","summary":"普洛药业(000739.SZ)公告称，公司与嘉兴安帝康生物科技签署《战略合作框架协议》，双方基于战略合作关系寻求在创新药物方向更多长期合作项目，共同打造行业竞争力，不断提升药物市场竞争优势和稳定供应能力。合作内容包括安帝康生物优先选择公司进行CDMO项目的研发和生产工作，公司为安帝康生物提供专业的CDMO服务；安帝康生物优先委托公司进行CDMO项目的研发和生产，并基于项目协议之约定许可公司使用安帝康生物提供的工艺和技术。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600032064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000739","BK0188","159837","BK0239","BK0060"],"gpt_icon":0},{"id":"2580498278","title":"港股前十月IPO募资额全球居首 生物科技板块表现亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2580498278","media":"财闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580498278?lang=zh_cn&edition=full","pubTime":"2025-11-04 08:37","pubTimestamp":1762216620,"startTime":"0","endTime":"0","summary":"今年以来，在政策支持及资金面回暖的背景下，港股市场成为热门上市地。数据显示，今年前10个月，港交所以超过2100亿港元的募资额在全球各大交易所中排名第一。截至11月3日，今年以来港股IPO ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251104/c672220812.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159837"],"gpt_icon":0},{"id":"2580289815","title":"生物科技企业密集上市 中国创新药加速全球化布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2580289815","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580289815?lang=zh_cn&edition=full","pubTime":"2025-11-02 20:36","pubTimestamp":1762086960,"startTime":"0","endTime":"0","summary":"当前中国创新药“出海”态势持续向好，越来越多企业凭借自主研发实力，通过多元化路径探索全球市场，在国际舞台上搭建起自己的话语体系。2025年中国创新药BD交易迎来爆发式增长，截至10月份 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20251102/c672181857.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251102/c672181857.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159837","159992"],"gpt_icon":0},{"id":"2579112449","title":"医药创新投资大会在南宁举办 港交所：香港重新成为生物科技企业首选上市目的地","url":"https://stock-news.laohu8.com/highlight/detail?id=2579112449","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579112449?lang=zh_cn&edition=full","pubTime":"2025-10-30 18:57","pubTimestamp":1761821853,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，由香港交易所与中国医药创新促进会联合主办的第十届中国医药创新与投资大会于10月26日至10月27日在南京成功举办。香港交易所一直致力于打造高效、多元的国际融资平台，为中国生物科技企业的发展注入资本动能。2025年市场明显回暖，香港重新成为生物科技企业首选的上市目的地。截至目前，香港已完成12宗生物科技IPO，合计融资13亿美元，融资总额位居全球首位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1362910.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359201885.HKD","LU0605514214.HKD","HEXmain","LU0197773160.USD","LU1282649810.SGD","IE00BKZH1Z71.USD","LU0417516738.SGD","LU0762540952.USD","LU0348816934.USD","SG9999002562.SGD","IE00BZ08YT58.USD","LU1048588211.SGD","IE00BZ08YR35.GBP","LU0577902454.USD","LU0831103253.SGD","80388","HKXCY","LU0061477393.USD","BK1574","IE00BZ08YS42.EUR","LU0819121731.USD","LU0149721374.USD","LU2039709279.SGD","SG9999001846.SGD","09939","LU1366334651.USD","SGXZ90724238.SGD","LU0197773673.USD","LU0348735423.USD","LU0607220059.USD","00388","LU2226246903.HKD","LU0797268264.HKD","LU0955669360.SGD","LU0594300419.USD","BK1610","LU0117841782.USD","159837","LU0251144936.SGD","LU0886674414.USD","LU0762541174.USD","SG9999001093.SGD","LU0211977185.USD","LU1051769294.HKD","LU1282648689.USD","LU0791590937.USD","BK1161","159938","LU0072462343.USD","LU0261947096.USD"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768255874957,"stockEarnings":[{"period":"1week","weight":0.0466},{"period":"1month","weight":0.061},{"period":"3month","weight":0.0094},{"period":"6month","weight":0.0802},{"period":"1year","weight":0.3114},{"period":"ytd","weight":0.0911}],"compareEarnings":[{"period":"1week","weight":0.0353},{"period":"1month","weight":0.0709},{"period":"3month","weight":0.0776},{"period":"6month","weight":0.1888},{"period":"1year","weight":0.3146},{"period":"ytd","weight":0.0495}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(159837)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(159837)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,159837,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(159837)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(159837)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}